This prospective, observational study evaluated breast cancer incidence in 1,268 women treated with subcutaneous testosterone (T) implants, either alone or in combination with the aromatase inhibitor anastrozole (T+A), over a 5-year interim period of a 10-year study. Participants received T or T+A for hormone deficiency symptoms. With a cumulative follow-up
